Login to Your Account



Sodium Ion Channels Pay Off

Icagen-Pfizer Deal: Potential $1B-Plus For Pain Therapies

By Randall Osborne


Wednesday, August 15, 2007
Icagen Inc.'s potential $1 billion-plus deal with Pfizer Inc. to develop sodium ion channel modulators for pain took the hurt out of a Phase III setback with senicapoc for sickle cell disease and the loss of two other pharma partners recently. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription